Leading the future of rare disease medicine for patients like Mason.

Ultragenyx was built from the ground up with a strong commitment to sustainability and a mindset to do the right thing for people with rare disease. Read more about our commitments in our Environmental, Social, and Governance Initiatives 2021 report, Going beyond – every day.

Our diverse portfolio of approved medicines and investigational therapies is advancing first- or best-in-class treatments for diseases that exhibit a clear biology for treatment and are severely underserved by current standard of care.

We maintain an environment that puts people first. This includes patients, their families and caregivers, and our employees. We respect the responsibility that comes with developing medicines for rare diseases.